Specifically, EGFR T790 M, the mutation responsible for over 50% of the acquired resistance post-TKI in EGFR-mutated lung cancers [61], emerges in cis with the initial drug-sensitizing EGFR mutation in the tumour as well [71]. Here, EGFR is linked to lung carcinoma.